Artwork for What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Perspectives on 2023 Updates From San Antonio
Keeping Current

What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Perspectives on 2023 Updates From San Antonio
00:00:00 / 00:30:44